Patents Assigned to Cephalon, Inc.
  • Use of reslizumab to treat moderate to severe eosinophilic asthma
    Patent number: 9815894
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 14, 2017
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah
  • CRYSTALLINE FORMS OF PARP INHIBITORS
    Publication number: 20170267683
    Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
    Type: Application
    Filed: November 25, 2015
    Publication date: September 21, 2017
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9623026
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 18, 2017
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Nanoparticulate and macroparticulate formulations
    Patent number: 9598377
    Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 21, 2017
    Assignee: Cephalon, Inc.
    Inventors: Peter D. Brown, Anthony S. Drager
  • Solid forms of bendamustine hydrochloride
    Patent number: 9533955
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 3, 2017
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Macrocyclic compounds as ALK, FAK and JAK2 inhibitors
    Patent number: 9487529
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 8, 2016
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Substituted aromatic sulfur compounds and methods of their use
    Patent number: 9475766
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: October 25, 2016
    Assignees: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • Pyrrolotriazines as ALK inhibitors
    Patent number: 9440984
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 13, 2016
    Assignee: Cephalon, Inc.
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Proteasome inhibitor delanzomib for use in the treatment of lupus
    Patent number: 9340559
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Bruce A. Ruggeri, Matthew M. Seavey
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9339502
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders
    Patent number: 9238656
    Abstract: This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 19, 2016
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Matthew A. Curry, Diane E. Gingrich, Keith S. Learn, Gregory R. Ott, Jason C. Wagner
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9132128
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: September 15, 2015
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Tricyclic derivatives and their pharmaceutical use and compositions
    Patent number: 9115147
    Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomeric forms, all mixtures of stereoisomeric forms, and salts of these compounds. This application also relates to compositions comprising compounds of Formula I, stereoisomeric forms, all mixtures of stereoisomeric forms, and salts thereof and uses therefor.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 25, 2015
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, George C. Morton, Gerard C. Rosse, Yi Wang
  • Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative
    Patent number: 9034876
    Abstract: This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: May 19, 2015
    Assignee: Cephalon, Inc.
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey
  • Janus kinase 2 (JAK2) inhibitor for the treatment of lupus
    Patent number: 9023853
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: May 5, 2015
    Assignee: Cephalon, Inc.
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey
  • PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF
    Publication number: 20150011759
    Abstract: The present invention provides a short, safe, inexpensive, commercially scalable process for preparing (R)- or (S)-2-methylpyrrolidine from 2-methylpyrroline, which does not require the isolation of synthetic intermediates.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 8, 2015
    Applicant: CEPHALON, INC.
    Inventors: Michael Christie, Joseph J Petraitis
  • Substituted pyridazine derivatives
    Patent number: 8912183
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 16, 2014
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Bendamustine pharmaceutical compositions
    Patent number: 8895756
    Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 25, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jason Edward Brittain, Joe Craig Franklin
  • Method for purifying a fused pyrrolocarbazole derivative
    Patent number: 8884014
    Abstract: The present invention relates a method for purifying a fused pyrrolocarbazole compound known as 11-isobutyl-2-methyl-8-(2-pyrimidinylamino)-2,5,6,11,12,13-hexahydro-4Hindazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one using an acid complex thereof. The present invention also relates to a crystalline form of the acid complex.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 11, 2014
    Assignees: Cephalon, Inc., Teva Sante
    Inventors: Shawn P. Allwein, Arnaud Grandeury, Guy Piacenza, Sebastien Rose
  • Solid forms of bendamustine hydrochloride
    Patent number: 8883836
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 11, 2014
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean